AIHTA - Publications - Search - Selpercatinib (Retsevmo®) as monotherapy for the treatment of advanced RET fusion positive non-small cell lung cancer (NSCLC)

Rothschedl, E. and Wolf, S. (2022): Selpercatinib (Retsevmo®) as monotherapy for the treatment of advanced RET fusion positive non-small cell lung cancer (NSCLC). Oncology Fact Sheet Nr. 95.

[thumbnail of Oncology Fact Sheet Nr.95.pdf]
Preview
PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
111kB

Item Type:Oncology Fact Sheet
Subjects:QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology
QZ Pathology > QZ 200-380 Neoplasms.Cysts
WB Practice of medicine > WB 300-962 Therapeutics
WF Respiratory system
Language:English
Series Name:Oncology Fact Sheet Nr. 95
Deposited on:16 May 2022 10:34
Last Modified:16 May 2022 10:34

Repository Staff Only: item control page